Malaria Vaccines

9 clinical trials · Condition

Record	Firm	Date
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (NCT02699099)	GlaxoSmithKline	2017-05-10
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa (NCT02251704)	GlaxoSmithKline	2014-10-22
Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) (NCT01345240)	GlaxoSmithKline	2011-11-17
Epidemiology Study of Malaria Transmission Intensity in Africa (NCT01190202)	GlaxoSmithKline	2011-03-14
Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine (NCT00977899)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2009-08-20
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants (NCT00289185)	GlaxoSmithKline	2006-09-27

Every clearance here is in the API, with alerts when new ones post.